Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1479 • ACR Convergence 2023
Risk Factors for Human Papillomavirus Cervical Infection and Clearance in Patients with Systemic Lupus Erythematosus: The PAPILUP Study
Tiphaine Goulenok¹, Valentine Marie Ferre², Celine Mendes¹, Lea Dayan³, Margot Bucau¹, Fatima Farhi¹, Thomas Papo² and Karim Sacre², ¹Assistance Publique Hopitaux de Paris, Paris, France, ²Université Paris Cité, Paris, France, ³Maison de Sante les Epinettes, Paris, France
Background/Purpose: An impaired clearance of cervical human papillomavirus (HPV) related to inadequate immune responses may result in persistent infection and increase the risk to develop…
Abstract Number: 1497 • ACR Convergence 2023
Eltrombopag in SLE-Associated Thrombocytopenia: Treatment Response and Thrombotic Complications
Asmaa Beltagy¹, Abeer Abdelati¹, Fatma Fayed², Nouran Eshak³, Ashraf Elghandour¹ and Mohamed Halaby⁴, ¹Faculty of Medicine, Alexandria University, Alexandria, Egypt, ²Alexandria University Student Hospital, Alexandria, Egypt, ³Mayo Clinic Arizona, Lubbock, TX, ⁴Faculty of Medicine, Alexandria University, Birmingham, AL
Background/Purpose: This study aimed to assess the efficacy of Eltrombopag, a medication used to treat thrombocytopenia, in patients with systemic lupus erythematosus (SLE)-associated thrombocytopenia. Additionally,…
Abstract Number: 1585 • ACR Convergence 2023
Defining Neutrophil-Mediated Renal Damage Triggered by Ultraviolet (UV) Skin Exposure
Angelique Cortez¹, Lindsay Mendyka², Fred Kolling³, Michael Whitfield¹ and Sladjana Skopelja-Gardner⁴, ¹Dartmouth College, Hanover, NH, ²Dartmouth Hitchcock, Lebanon, NH, ³Geisel School of Medicine at Dartmouth, Hanover, NH, ⁴Dartmouth-Hitchcock, Lebanon, NH
Background/Purpose: Lupus (SLE) is one of the leading causes of death in young women in the United States. Roughly ~80% of SLE patients experience sensitivity…
Abstract Number: 1681 • ACR Convergence 2023
Tacrolimus Use in SLE Pregnancy and Its Effect on Pregnancy Outcomes: Retrospective Study in Two Japanese Tertiary Referral Centers
Takehiro Nakai¹, Nanase Honda², Eri Soga², Sho Fukui³, Ayako Kitada¹, Naoto Yokogawa⁴ and Masato Okada¹, ¹St. Luke's International Hospital, Tokyo, Japan, ²Tokyo Metropolitan Tama Medical Center, Tama, Japan, ³Brigham and Women's Hospital, Boston, MA, ⁴Tokyo Metropolitan Tama Medical Center, Taito City, Tokyo, Japan
Background/Purpose: Tacrolimus is one of the major treatment options of systemic lupus erythematosus (SLE) and is thought to be pregnancy compatible medication. Since little is…
Abstract Number: 1871 • ACR Convergence 2023
Utility of Infrared Thermography in Patients with Digital Gangrene
Nidhish Chandra M, Puneet Kumar, Urmila Dhakad, Shweta Bhardwaj, Sanjay Pruthviraj Buddha, Parag Vijayvergia and Lily Singh, King George Medical University, Lucknow, India
Background/Purpose: Digital gangrene has been described as a complication of several Autoimmune Inflammatory Rheumatic Diseases(AIIRD). Due to multiple underlying mechanisms causing digital gangrene in AIIRD…
Abstract Number: 2262 • ACR Convergence 2023
Identifying Important Domains for Inclusion in a Novel Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE): Results of a Modified Delphi Study
Kathryn Connelly¹, Rachel Koelmeyer¹, Darshini Ayton¹, Raychel Barrallon¹, Laura Eades², Vera Golder³, Kate gregory¹, John May¹, Rangi Kandane-Rathnayake³, Maisarah Mydin¹, Munni Akther¹, Afia Anzum¹, Jeanette Andersen⁴, Hermine Brunner⁵, Cynthia Aranow⁶, Laurent Arnaud⁷, Anca Askanase⁸, Catherine Barbey⁹, Joy Buie¹⁰, Laurie Burke¹¹, Alain Cornet¹², Karen Costenbader¹³, Maria Dall'Era¹⁴, Joan Merrill¹⁵, Khadija Dantata¹⁶, Alan Friedman¹⁷, Richard Furie¹⁸, Sandra Garces¹⁹, Maja Hojnik²⁰, Kenneth Kalunian²¹, Justine Maller²², Patrick Marquis²³, Marta Mosca²⁴, Erika Noss²⁵, Guillermo Pons-Estel²⁶, Lee Simon²⁷, Eve Smith²⁸, Alessandro Sorrentino²⁹, Anna Stevens³⁰, George Stojan³¹, Ying Sun³², Yoshiya Tanaka³³, Ed Vital³⁴, Ronald van Vollenhoven³⁵, Victoria P. Werth³⁶ and Eric Morand³⁷, ¹Monash University, Clayton, Australia, ²Monash Health and Monash University, Clayton, Australia, ³Monash University, Department of Medicine, Sub-faculty of Clinical and Molecular Medicine, Clayton, Australia, ⁴Lupus Europe, Knebel, Denmark, ⁵Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH, ⁶Feinstein Institutes for Medical Research, Manhasset, NY, ⁷University Hospitals of Strasbourg, Strasbourg, France, ⁸Columbia University Medical Center, New York, NY, ⁹Biogen, Baar, Switzerland, ¹⁰Lupus Foundation of America, York, SC, ¹¹LORA Group, Normal, IL, ¹²Lupus Europe, Brussels, Belgium, ¹³Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ¹⁴University of California San Francisco, San Francisco, CA, ¹⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁶Lupus Foundation of America, Richmond Hill, GA, ¹⁷AbbVie, Inc., North Chicago, IL, ¹⁸Northwell Health, Manhasset, NY, ¹⁹Amgen, Inc., Thousand Oaks, CA, ²⁰Eli Lilly and Company, Indianapolis, IN, ²¹University of California San Diego, La Jolla, CA, ²²Genentech, Inc., Half Moon Bay, CA, ²³Modus Outcomes, Newton, MA, ²⁴Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ²⁵Janssen Research and Development, Dresher, PA, ²⁶CREAR, Rosario, Argentina, ²⁷SDG LLC, West Newton, MA, ²⁸University of Liverpool, Liverpool, United Kingdom, ²⁹Medical Affairs, AstraZeneca, Cambridge, United Kingdom, ³⁰Bristol Myers Squibb, Groton, CT, ³¹UCB, Baltimore, MD, ³²the healthcare business of Merck KGaA, Darmstadt, Germany, ³³University of Occupational and Environmental Health, Kitakyushu, Japan, ³⁴University of Leeds, Leeds, United Kingdom, ³⁵Amsterdam University Medical Centers, Amsterdam, Netherlands, ³⁶University of Pennsylvania, Wynnewood, PA, ³⁷Monash University, Centre for Inflammatory Diseases, Melbourne, Australia
Background/Purpose: The Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE) is a novel clinical outcome assessment (COA) for SLE randomized controlled trials (RCTs), being developed…
Abstract Number: 2279 • ACR Convergence 2023
Sociodemographic Features, Health-Related Quality of Life (HRQoL), Previous General Self-Efficacy and Corticosteroids (CS) Are Associated with General Self-Efficacy in Systemic Lupus Erythematosus (SLE) Patients. Data from a Prevalent Latin American Lupus Cohort
Manuel Ugarte-Gil¹, Rocío Gamboa-Cárdenas², Cristina Reategui-Sokolova³, Victor Pimentel-Quiroz², Claudia Elera-Fitzcarrald⁴, Jorge M. Cucho-Venegas⁵, Cesar Pastor-Asurza⁶, Zoila Rodriguez-Bellido⁶, Risto Perich-Campos⁶ and Graciela S Alarcón⁷, ¹Universidad Cientifica del Sur, Lima, Peru, ²Universidad Cientifica del Sur/Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, ³Hospital Guillermo Almenara Irigoyen, EsSalud/Universidad San Ignacio de Loyola, Lima, Peru, ⁴Hospital Guillermo Almenara Irigoyen, EsSalud/Universidad Privada San Juan Bautista, Lima, Peru, ⁵Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, ⁶Hospital Guillermo Almenara Irigoyen, EsSalud/Universidad Nacional Mayor de San Marcos, Lima, Peru, ⁷Heersink School of Medicine. The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Self-efficacy is the belief that one can carry out a behavior necessary to reach a desired goal. A better self-efficacy has been reported as…
Abstract Number: 2296 • ACR Convergence 2023
Association Between EQ-5D-5L and SLEDAI Scores in Patients with Systemic Lupus Erythematosus in the United States and Europe: A Real-world Survey
Ebuwa Igho-Osagie¹, Rezaul Khandker¹, Jack Milligan², Emily Goddard² and Sophie Barlow², ¹Merck & Co. Inc., Rahway, NJ, ²Adelphi Real World, Bollington, United Kingdom
Background/Purpose: The EQ-5D-5L is validated for estimating health related quality of life (HRQoL) across a variety of different disease areas, including rheumatic diseases. However, its…
Abstract Number: 2312 • ACR Convergence 2023
Fungal Infections in Hospitalized Patients of Systemic Lupus Erythematosus: A Nationwide Cohort Analysis
Saman Tanveer and Chun Pan, John H. Stroger Jr. Hospital of Cook County, Chicago, IL
Background/Purpose: Immunosuppressive therapy is the cornerstone of management in patients with systemic lupus erythematosus (SLE). Patients on immunosuppressive therapy are at increased risk of developing…
Abstract Number: 2328 • ACR Convergence 2023
Deucravacitinib, an Oral, Allosteric, Tyrosine Kinase 2 (TYK2) Inhibitor, in Patients with Active Systemic Lupus Erythematosus: Patient-Reported Outcomes in a Phase 2 Trial
Marta Mosca¹, Laurent Arnaud², Anca Askanase³, Coburn Hobar⁴, Brandon Becker⁵, Shalabh Singhal⁴, Subhashis Banerjee⁴, Samantha Pomponi⁴, Jiyoon Choi⁵, Adrian Coles⁵ and Vibeke Strand⁶, ¹Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ²University Hospitals of Strasbourg, Strasbourg, France, ³Columbia University Medical Center, New York, NY, ⁴Bristol Myers Squibb, Princeton, NJ, ⁵Bristol Myers Squibb, Lawrenceville, NJ, ⁶Stanford University, Portola Valley, CA
Background/Purpose: Deucravacitinib is a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor approved in the US, EU, and other countries for treatment of adults…
Abstract Number: 2348 • ACR Convergence 2023
Incidence of Infections Among Adult Patients with SLE Treated with Belimumab (BEL): Pooled Data from Three Open-Label Extension Studies over 11+ Years
Jinoos Yazdany¹, Kenji Oku², Luciana Seguro³, Paula Curtis⁴, Yoshifumi Inagaki⁵, Roger A. Levy⁶ and Andrea Doria⁷, ¹University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA, ²Kitasato University School of Medicine, Department of Rheumatology and Infectious Diseases, Kanagawa, Japan, ³Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Rheumatology Division, Universidade de Sao Paulo, São Paulo, Brazil, ⁴GlaxoSmithKline, R&D Biostatistics, Brentford, United Kingdom, ⁵GlaxoSmithKline, Global Medical Affairs, Brentford, United Kingdom, ⁶GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, ⁷University of Padova, Rheumatology Unit, Department of Medicine, Padova, Italy
Background/Purpose: BEL-treated patients (pts) in clinical trials and long-term extension (LTE) studies1-7 experienced comparable incidence of infections versus those treated with standard therapy (ST) alone…
Abstract Number: 2485 • ACR Convergence 2023
Comparative Risk of Serious Psychiatric Events with Belimumab versus Oral Immunosuppressant Use in Patients with Systemic Lupus Erythematosus
April Jorge¹, Baijun Zhou¹, Yuqing Zhang² and Hyon K. Choi³, ¹Massachusetts General Hospital, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital and Harvard Medical School, Lexington, MA
Background/Purpose: In randomized placebo-controlled trials, including the phase 4 Belimumab Assessment of Safety in SLE study, belimumab use was associated with a higher incidence of…
Abstract Number: 2554 • ACR Convergence 2023
Validation of a Flare Risk Index Informed by Select Immune Mediators in Systemic Lupus Erythematosus in a Confirmatory Cohort
Melissa Munroe¹, Derek Blankenship², Daniele DeFreese², Adrian Holloway², Mohan Purushothaman², Wade DeJager³, Susan Macwana³, Joel Guthridge³, Stan Kamp³, Nancy Redinger³, Teresa Aberle³, Eliza Chakravarty³, Cristina Arriens⁴, Yanfeng Li⁵, Hu Zeng⁵, Stephanie Dezzutti⁶, Peter Izmirly⁷, Uma Thanarajasingam⁵, Diane L. Kamen⁶, Jill Buyon⁸, Judith James³ and Eldon Jupe², ¹Oklahoma Medical Research Foundation; Progentec Diagnostics, Inc., Oklahoma City, OK, ²Progentec Diagnostics, Inc., Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Oklahoma Medical Research Foundation and University of Oklahoma Health Sciences Center, Department of Arthritis & Clinical Immunology, Oklahoma City, OK, ⁵Mayo Clinic, Rochester, MN, ⁶Medical University of South Carolina, Charleston, SC, ⁷New York University School of Medicine, New York, NY, ⁸NYU Grossman School of Medicine, New York, NY
Background/Purpose: SLE is marked by immune dysregulation linked to varied clinical disease activity. Using a unique confirmatory cohort of SLE patients, this study seeks to…
Abstract Number: 0121 • ACR Convergence 2023
High Prevalence of Mental Health Disorders Among Patients with Rheumatoid Arthritis and Systemic Lupus Erythematosus
Jeong Yee¹, Candace Feldman¹, Emily G. Oakes¹, Elizabeth Karlson¹, Jack Ellrodt¹, Laura Kubzansky², Karestan Koenen² and Karen Costenbader³, ¹Brigham and Women's Hospital, Boston, MA, ²Harvard T.H. Chan School of Public Health, Boston, MA, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) are complex autoimmune diseases associated with pain and decreased quality of life. Mental health conditions related…
Abstract Number: 0186 • ACR Convergence 2023
Retention in Rheumatology Care and on Hydroxychloroquine and SLE Outcomes by Neighborhood Disadvantage: A Medicare Cohort Study of Acute Care and Kidney Failure
Christie M. Bartels¹, Ang Yu², Felix Elwert², Andrea Gilmore-Bykovskyi³, W. Ryan Powell⁴, Shivani Garg⁵ and Amy J. Kind⁴, ¹University of Wisconsin, School of Medicine and Public Health, Madison, WI, ²Department of Sociology, University of Wisconsin, Madison, WI, ³Berbee Walsh Department of Emergency Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁴Center for Health Disparities Research, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁵Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Gaps in systemic lupus (SLE) care are believed to contribute to higher kidney failure (ESKD), acute care use, mortality, and disease damage in US…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].